Varian Medical Systems — 2018 ASTRO Investor Relations Meeting
67 slides from Varian Medical Systems's conference presentation, Oct 23, 2018

Slide 1: 2018 ASTRO Investor Relations Meeting: Transforming Cancer Care
2018 ASTRO Investor Relations Meeting October 23, 2018 Transforming Cancer Care

Slide 2: Agenda
FOR INVESTOR USE ONLY Agenda Welcome & Introductions Mike Bruff SVP, Investor Relations, Corporate Planning & Segment Finance Varian Overview & Strategic Framework Dow Wilson President and Chief Executive Officer Innovations in Oncology Kolleen Kennedy Chief Growth Officer and President , Proton Sol

Slide 3: Forward-Looking Statements
This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward - Looking Statements Except for historical information, this presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 199

Slide 4: Varian Overview & Strategic Framework
FOR INVESTOR USE ONLY Varian Overview & Strategic Framework Dow Wilson President and Chief Executive Officer

Slide 5: Varian today – a snapshot
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Varian today – a snapshot A focused cancer company Global Leader in radiation therapy FY17 revenues $2.6B >8,000 medical linear accelerators >40 worldwide training centers software installs 5,000 proton the

Slide 6: Cancer affects everyone
VARIAN CONFIDENTIAL/ PROPRIETARY: DISCLOSED SOLELY FOR IMMEDIATE RECIPIENT ONLY $2 Trillion Global Economic Burden in 2010 $$$ 24.6 Million New Cancer Cases by 2030 10% Cancer Patients That Have Access To RT in Low Income Countries > 20,000* Linacs needed by 2035; greatest need in low + mid - income

Slide 7: Long-term growth and value creation strategy
Long - term growth and value creation strategy Global Leader in Radiation Therapy Radiation oncology OIS Radiosurgery Brachytherapy Radiation oncology treatment planning Proton therapy Radiation therapy Global Leader in Multi - Disciplinary, Integrated Cancer Care Solutions Interventional oncology S

Slide 8: Varian investments in innovation
FOR INVESTOR USE ONLY Varian investments in innovation Achieving a world without fear of cancer Integrated Care Moving beyond the current fragmented cancer care landscape toward a more integrated approach to cancer care Treatment Enabling clinicians to deliver guideline driven, multi - modality prec

Slide 9: Integrated Care
FOR INVESTOR USE ONLY Integrated Care Moving beyond the current fragmented cancer care landscape toward a more integrated approach to cancer care Treatment Enabling clinicians to deliver guideline driven, multi - modality precision treatments with advanced radiation therapy, surgical procedures, int

Slide 10: Integrated Care
FOR INVESTOR USE ONLY Integrated Care Moving beyond the current fragmented cancer care landscape toward a more integrated approach to cancer care Treatment Enabling clinicians to deliver guideline driven, multi - modality precision treatments with advanced radiation therapy, surgical procedures, int

Slide 11: Integrated Care
FOR INVESTOR USE ONLY Integrated Care Moving beyond the current fragmented cancer care landscape toward a more integrated approach to cancer care Treatment Enabling clinicians to deliver guideline driven, multi - modality precision treatments with advanced radiation therapy, surgical procedures, int

Slide 12: Innovation leader in radiation therapy
Innovation leader in radiation therapy Integrated hardware and software solutions Treatment Delivery & Imaging Hardware makes up ~40% Varian’s business BRACHYTHERAPY HALCYON PROTONS TRUEBEAM FAMILY ADAPTIVE Work in progress; not available for sale Services Services make up ~40% Varian’s business HAR

Slide 13: Leadership by the numbers
Leadership by the numbers First in installed base, customer satisfaction and investment in innovation $1B+ Services business Top rated service provider globally Varian rated #1 IMV Net Promoter Score of 71 1.5M+ SRS and SBRT cases on Varian machines 24 operational proton rooms >8,000 Largest install

Slide 14: Executing on long-term growth strategy
FOR INVESTOR USE ONLY FOR INVESTOR USE ONLY Executing on long - term growth strategy • TrueBeam, ARIA, and Eclipse named 2018 Best in KLAS category leaders • Launched Halcyon 2.0 with kV CBCT imaging • Acquired Mobius Medical Systems and humediQ Key accomplishments – FY 2018 Strengthen Leadership in

Slide 15: Organizing for future growth and success
FOR INVESTOR USE ONLY Organizing for future growth and success Expanded roles for Varian business leaders • Focus on driving further growth • Expand Proton Solutions offering • FlashForward • Acquisition Integration Office • Strategic Program Management Kolleen Kennedy Chief Growth Officer President

Slide 16: Innovations in Oncology
VARIAN CONFIDENTIAL – INTERNAL USE ONLY Innovations in Oncology Kolleen Kennedy Chief Growth Officer and President, Proton Solutions Chris Toth President, Oncology Systems Corey Zankowski SVP, Oncology Software Solutions

Slide 17: ASTRO booth 2018 Featured Products
ASTRO booth 2018 Featured Products New Portfolio Works - in - Progress ProBeam ® 360 ° Eclipse™ MCO Bravos™ Brachytherapy Halcyon™ KV HyperArc™ ARIA ® Mobile Velocity™ RapidSphere 360 Oncology™ Evinance Vision for Adaptive Therapy Mobius / DoseLab humediQ / Identify Evinance Noona FOR INVESTOR USE O

Slide 18: ASTRO events
ASTRO events • Varian Users Meeting: >1,300 attendees − Community Key Opinion Leader Presentations • Expanding Access to Care through Innovative Clinical School Faculty Program • Comprehensive Research Partner Meetings • Innovations in Proton Therapy Event • SANTRO 10th Anniversary & China Users Eve

Slide 19: Oncology Systems
Oncology Systems Chris Toth President, Oncology Systems

Slide 20: TrueBeam
VARIAN CONFIDENTIAL – INTERNAL USE ONLY TrueBeam ® >2,000 systems installed Exquisite imaging • Visualization of more targets TrueBeam has treated more SRS/SBRT cases than any other RT platform TrueBeam fueling replacement cycle and take - outs • Versatility driving competitive replacements • Clinac

Slide 21: HyperArc: Removing boundaries in brain radiosurgery
VARIAN CONFIDENTIAL – INTERNAL USE ONLY John Fiveash , MD Vice Chair, Academic Programs University of Alabama Birmingham NCI Designated Cancer Center FOR INVESTOR USE ONLY 21 HyperArc ™ ( TrueBeam ® platform) Removing boundaries in brain radiosurgery

Slide 22: Halcyon radiotherapy system
VARIAN CONFIDENTIAL – INTERNAL USE ONLY Halcyon Countries cleared in >100 Patients treated >5,000 Average uptime 99% Average installation time 7 days “As of 16 th October 2018, we are treating 131 patients in Halcyon Linac installed at Sterling Hospital, Rajkot in just about 15 hours comfortably . T

Slide 23: Halcyon clinical capabilities
VARIAN CONFIDENTIAL – INTERNAL USE ONLY Images courtesy of Washington University, St. Louis, School of Medicine Breast – Iterative CBCT Left Breast; Supine Scan Mode: Thorax Fast Scan Time: 17 sec; Breath Hold Dose: 5.9 mGy Prostate – Iterative CBCT Prostate; Supine Scan Mode: Pelvis Large Scan Time

Slide 24: Adaptive solution for every patient
VARIAN CONFIDENTIAL – INTERNAL USE ONLY • Artificial Intelligence (AI) driven • Multi - modality imaging at the console − MR, PET, CT • 4D prescriptions • Designed to image and treat fast − Greater patient comfort − Higher image quality • Uncompromised delivery hardware FOR INVESTOR USE ONLY 24 Note

Slide 25: Adaptive use case - Pancreas
VARIAN CONFIDENTIAL – INTERNAL USE ONLY • AI segmentation of the Pancreas − Using hi - res iCBCT images − In seconds FOR INVESTOR USE ONLY 25 Note: Adaptive is work - in - progress and not available for sale in any market. Adaptive use case - Pancreas

Slide 26: Halcyon: New levels of visualization in CT imaging
VARIAN CONFIDENTIAL – INTERNAL USE ONLY FOR INVESTOR USE ONLY 26 Hyun Kim, MD Assistant Professor of Radiation Oncology Washington University NCI Designated Cancer Center Halcyon™ New levels of visualization in CT imaging

Slide 27: AI driven multimodality adaptive therapy
VARIAN CONFIDENTIAL – INTERNAL USE ONLY AI driven multimodality adaptive therapy All modalities – every patient – without compromise MR Linac PET Linac CT Linac Varian AI driven multimodality adaptive therapy system Multimodality views exist today from same dataset outside of healthcare, Varian is b

Slide 28: Patient-centered design
VARIAN CONFIDENTIAL – INTERNAL USE ONLY Patient - centered design Enhancing patient experience, while improving care paradigm 70cm bore (Others) 100cm bore (Varian) “ ” There’s no wait time for patients and the machine is very quiet . - Kathleen Luyten , Therapist, Universitaire Ziekenhuizen Leuven

Slide 29: Strengthening the core through acquisitions
VARIAN CONFIDENTIAL – INTERNAL USE ONLY Strengthening the core through acquisitions FOR INVESTOR USE ONLY 29 Quality Assurance: Mobius QA Announced Feb 2018 • DoseLab and Mobius 3D • Total QA Market Opportunity: FY23: $125M Surface Guidance: humediQ IDENTIFY Announced Aug 2018 • IDENTIFY CT, RT, SGR

Slide 30: Brachytherapy: Introducing BRAVOS
VARIAN CONFIDENTIAL – INTERNAL USE ONLY Brachytherapy Introducing BRAVOS™ – new HDR afterloader Adding HDR brachy to external beam increases survival by 12 - 13% in Cervical and Prostate cancers New afterloader & applicators fueling market • Streamlined workflow efficiency/patient experience • 3D Pr

Slide 31: Oncology Software Solutions
Oncology Software Solutions Corey Zankowski SVP, Oncology Software Solutions

Slide 32: Disrupting our market with software, data and technology
VARIAN CONFIDENTIAL – INTERNAL USE ONLY VARIAN CONFIDENTIAL – INTERNAL USE ONLY • Migrate to SaaS & cloud solutions • Use informatics to create customer value • Offer services based on automation • Expand into new cancer care modalities Oncology Software Solutions Disrupting our market with software

Slide 33: Unlocking the $3B software opportunity
VARIAN CONFIDENTIAL – INTERNAL USE ONLY $250M $400M $550M $150M $550M Oncology Software Solutions Unlocking the $3B opportunity in our nearly 5,000 unique software sites* Eclipse ™ Treatment Planning $950M Velocity ® Image Management ARIA ® Oncology EMR FullScale™ Managed Services HyperArc | $450M R

Slide 34: Unlocking the $3B software opportunity
VARIAN CONFIDENTIAL – INTERNAL USE ONLY $250M $400M $550M $150M $550M Oncology Software Solutions Unlocking the $3B opportunity in our nearly 5,000 unique software sites* Eclipse ™ Treatment Planning $950M Velocity ® Image Management ARIA ® Oncology EMR FullScale™ Managed Services HyperArc | $450M R

Slide 35: Noona
VARIAN CONFIDENTIAL – INTERNAL USE ONLY Noona Patient reported outcomes (PRO) and symptom management solution Capture high quality oncology PRO data through highly engaged patients Proactively manage patient symptoms to improve outcomes Provide Real World Evidence services for life sciences companie

Slide 36: Patient reported outcomes
VARIAN CONFIDENTIAL – INTERNAL USE ONLY Patient reported outcomes Improving survival, lowering costs with smart symptom management Use of ePRO solutions result in: 20% fewer ER visits 30 - 50% fewer clinic calls 10% fewer hospitalizations 20 - 35% improved survival rate Symptom Monitoring With Patie

Slide 37: Integrates the cancer care continuum
VARIAN CONFIDENTIAL – INTERNAL USE ONLY Physician Mobile Nurse Navigation Flow sheet Symptom Management Multidisciplinary tumor board Care Team Coordination Practice Management Varian software 2018 Medical Oncology Radiation Oncology RT chart rounds Treatment planning Drug ordering Simulation Treatm

Slide 38: Evidence-based operating system for value-driven cancer care
VARIAN CONFIDENTIAL – INTERNAL USE ONLY Physician Mobile Nurse Navigation Flow sheet Symptom Management Multidisciplinary tumor board Care Team Coordination Practice Management Varian software 2023 Medical Oncology Radiation Oncology RT chart rounds Treatment planning as - a - service Drug ordering

Slide 39: Proton Solutions
Proton Solutions Kolleen Kennedy Chief Growth Officer & President, Proton Solutions

Slide 40: ProBeam proton therapy family
VARIAN CONFIDENTIAL/ PROPRIETARY: DISCLOSED SOLELY FOR IMMEDIATE RECIPIENT ONLY ProBeam ® proton therapy family Introducing ProBeam ® 360 ° Proton Therapy System ProBeam ® Single - Room ProBeam ® Multi - Room FOR INVESTOR USE ONLY 40

Slide 41: Introducing ProBeam 360° proton therapy system
VARIAN CONFIDENTIAL/ PROPRIETARY: DISCLOSED SOLELY FOR IMMEDIATE RECIPIENT ONLY 180 m 2 Introducing ProBeam ® 360 ° proton therapy system Future - forward Ultra - high dose rates Exceptional precision 360 ° gantry 25% lower vault cost FOR INVESTOR USE ONLY 41

Slide 42: New Horizons in Cancer Care
VARIAN CONFIDENTIAL – INTERNAL USE ONLY New Horizons in Cancer Care Dee Khuntia, MD Chief Medical Officer

Slide 43: Medical Affairs agenda
MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY Image here that’s relevant to MA? Agenda 1. SABR - COMET trial Stereotactic Ablative RT for the Comprehensive Treatment of Oligometastatic Tumors 2. Hippocampal avoidance WBRT Phase 3 trial Preservation of Neurocognitive Function with Conform

Slide 44: SBRT improved overall survival in randomized trial
MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY SBRT improved overall survival by 50% and doubled progression - free survival in randomized controlled trial Plenary Abstract #5 Stereotactic Ablative RT for the Comprehensive Treatment of Oligometastatic Tumors (SABR - COMET): Results of a r

Slide 45: Hippocampal avoidance WBRT Phase 3 trial
MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY FOR INVESTOR USE ONLY Conformal avoidance of hippocampus during whole - brain radiotherapy for brain metastases shown to preserve neurocognitive function in Phase 3 trial Brain Mets • ~300K new cases of brain metastases each year in the U.S •

Slide 46: Using advanced IMRT to spare memory
MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY FOR INVESTOR USE ONLY Using advanced IMRT to spare memory: the challenge Even low doses to hippocampus damages memory FOR INVESTOR USE ONLY 46 Adapted from Kempermann & Neumann Science 302: 1689 (2003) Avoiding Hippocampus saves memory

Slide 47: Hippocampal-sparing whole-brain radiation therapy
MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY 47 Hippocampal - sparing whole - brain radiation therapy – Like treating a donut while sparing the center FOR INVESTOR USE ONLY 47

Slide 48: Hippocampal avoidance trial results
MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY STUDY DESIGN RESULTS 518 patient randomized trial Whole brain RT (WBRT) vs Hippocampal Avoidance WBRT Median follow - up of 6.1 months Time to neurocognitive failure was longer with Hippocampal Avoidance Neurocognitive failure at 6 months was

Slide 49: RapidPlan model for hippocampal sparing
MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY Model trained from dozens of expertly planned hippocampal sparing plans Hippocampal - sparing whole brain RT RapidPlan model can be completed in minutes Varian and Northwestern University Anthony Magliari (Varian) Vinai Gondi and Robert Foste

Slide 50: Innovative solutions addressing market demand
MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY Innovative solutions addressing market demand Clinical realization to market impact FOR INVESTOR USE ONLY 50 $8.7B Installed Base replacement opportunity* TrueBeam ® Halcyon ™ $3B Software Portfolio Opportunity* Eclipse ™ Tx Planning Velocity

Slide 51: FlashForward
FlashForward Dee Khuntia, MD Chief Medical Officer

Slide 52: Ultra high dose rates
500 1000 1500 2000 2500 400 cGy 2,400 cGy TrueBeam Clinac TrueBeam Clinac ProBeam Flash ProBeam 2000 4000 6000 8000 10000 Flash 720,000 cGy 0 cGy 100000 200000 300000 400000 720000 500000 Per min 10,000 cGy Ultra high dose rates Flash Range 40 Gy/sec – 120 Gy/sec FOR INVESTOR USE ONLY Source: Varian

Slide 53: Flash spares normal tissue
MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY Flash spares normal tissue Control 0 Gy/s Standard RT 17 Gy 0.03 Gy/s FLASH 17 Gy 60 Gy/s NORMAL TISSUE SIGNIFICANT FIBROSIS NO APPARENT DAMAGE FOR INVESTOR USE ONLY 53 From Favaudon et al., Sci. Transl. Med., 16 Jul 2014: Vol. 6, Issue 245,

Slide 54: Flash spares normal tissue while maintaining tumor control
MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY Flash spares normal tissue while maintaining tumor control High dose rate electron RT – published pre - clinical results Flash increases normal tissue sparing compared to conventional dose rate Better tissue sparing with increasing dose rates

Slide 55: Varian pre-clinical proton experiments
MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY FOR INVESTOR USE ONLY Varian pre - clinical proton experiments Varian proton experiments FOR INVESTOR USE ONLY 55 Control Conventional protons (1 Gy/sec) Flash protons (40Gy/sec) 3 Groups 392 Mice Age and sex matched 6 Cohorts Sacrificed 1h -

Slide 56: Flash reduced dermatitis and fibrosis
MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY Flash resulted in a reduction in radiation induced dermatitis and fibrosis Normal tissue toxicity studies *Average fibrosis scores 25% DERMATITIS 35% reduction in dermatitis* with FLASH vs. Conventional (17.5 Gy) *Average dermatitis scores Co

Slide 57: Normal tissue and tumor control studies underway
MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY Brain Lung Head and Neck Fibrosis induction in tumor microenvironment mimicking normal tissue Neurocognitive evaluation of rats after Flash and conventional radiation Induction of Oral mucositis in mice Normal tissue and tumor control studies

Slide 58: Tumor control preliminary results
MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY FOR INVESTOR USE ONLY Tumor control preliminary results: Proton FLASH vs Proton Conventional vs No RT 58 Approximate tumor volume (mm^3) Treatment group Control (Untreated) (n=12) 20 40 60 0 Flash (n=24) Conventional (n=24) 50 30 10 70 Tumor

Slide 59: Flash reduces differential gene expression
Normal Lung Tissue Conventional Protons Flash Protons 1,294 639 37 40 Flash reduces differential gene expression normally observed with radiation therapy Different genes are up or down regulated when comparing treatment groups versus the (untreated) control group. FLASH Protons have a gene expressio

Slide 60: Flash offers potential for paradigm shift
VARIAN CONFIDENTIAL – INTERNAL USE ONLY VARIAN CONFIDENTIAL – INTERNAL USE ONLY There are very few technologies that come along that offer a potential for paradigm shift – Flash offers that potential. – James M. Metz, MD Professor and Chair Radiation Oncology Executive Director, OncoLink Penn Medici

Slide 61: FlashForward Consortium
FlashForward ™ Consortium Sylvester Comprehensive Cancer Center New York Proton Center Paul Scherrer Institute Holland PTC Particle Therapy Centre University College London Cincinnati Proton Therapy Center University of Maryland Dept of Radiation Oncology Emory Proton Therapy Center Proton Internati

Slide 62: Closing Remarks
VARIAN CONFIDENTIAL/ PROPRIETARY: DISCLOSED SOLELY FOR IMMEDIATE RECIPIENT ONLY 62 Closing Remarks Dow Wilson President and Chief Executive Officer

Slide 63: In summary, we are…
FOR INVESTOR USE ONLY In summary, we are… 63 …Driving toward our vision of a world without fear of cancer Delivering on our long - term growth and value creation strategy Growing our net installed base Extending our market - leading, best - in - class product portfolio Becoming a global leader in mu

Slide 64: Q&A
Q&A

Slide 65: Appendix
VARIAN CONFIDENTIAL – INTERNAL USE ONLY Appendix

Slide 66: SBRT outcomes for prostate cancer
MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY SBRT delivers impressive cancer control for patients with prostate cancer in largest analysis of long - term SBRT outcomes CONCLUSION “To the best of our knowledge, this is the largest analysis of long - term outcomes following SBRT for PCa,

Slide 67: Innovation leader in radiation therapy
MEDICAL AFFAIRS | VARIAN CONFIDENTIAL – INTERNAL USE ONLY Innovation leader in radiation therapy Integrated hardware and software solutions Treatment Delivery & Imaging Hardware makes up ~40% Varian’s business Digital Health Solutions Software makes up ~20% Varian’s business BRACHYTHERAPY » Integrat
Source: SEC EDGAR · 8-K filed Oct 23, 2018
More decks from Varian Medical Systems Inc
Q1 FY2021 Earnings Presentation29 slides · Jan 26, 2021
Q4 FY2020 Earnings Presentation30 slides · Oct 27, 2020
Merger or Acquisition (August 2020)33 slides · Aug 4, 2020
Merger or Acquisition (August 2020)18 slides · Aug 3, 2020
Q3 FY2020 Earnings Presentation36 slides · Aug 3, 2020
Q2 FY2020 Earnings Presentation36 slides · May 4, 2020